Sigma Takes 10% Stake as Pharmx Becomes Preferred EDI Provider in ANZ
Pharmx Technologies has entered a multi-year strategic alliance with Sigma Healthcare, becoming the preferred EDI provider for Sigma and Chemist Warehouse across Australia and New Zealand, while Sigma takes a significant equity stake.
- Pharmx becomes preferred EDI provider for Sigma and Chemist Warehouse in ANZ
- Sigma subscribes to 10% of Pharmx shares, with potential to increase to 19.9%
- Sigma gains a seat on Pharmx’s board, reinforcing strategic partnership
- Pharmx to pay Sigma an $8.7 million establishment fee
- Alliance aims to modernise pharmacy supply chains and support global expansion
Strategic Alliance Announcement
Pharmx Technologies Limited (ASX: PHX) has formalised a significant multi-year strategic alliance with Sigma Healthcare Limited (ASX: SIG), one of Australia’s foremost pharmaceutical wholesalers and retail pharmacy operators. This partnership positions Pharmx as the preferred Electronic Data Interchange (EDI) service provider for Sigma’s wholesale operations and the Chemist Warehouse retail network across Australia and New Zealand.
With Sigma servicing over 3,000 pharmacy customers, including 850 Chemist Warehouse, Amcal, and Discount Drug Stores franchises, this alliance substantially expands Pharmx’s footprint in the pharmacy technology sector. The agreement also includes Sigma’s international stores in Ireland, UAE, and New Zealand, setting the stage for broader global collaboration.
Equity Stake and Board Representation
As part of the deal, Sigma will subscribe to approximately 59.95 million Pharmx shares, representing 10% of Pharmx’s issued capital, and will secure a seat on Pharmx’s board. This equity participation underscores the strategic depth of the alliance, moving beyond a traditional vendor-customer relationship to a scalable partnership. Sigma may increase its stake up to 19.9% over time, subject to shareholder approval and escrow conditions.
Pharmx will also pay Sigma an $8.7 million establishment fee, reflecting the long-term commitment and mutual confidence in the partnership’s potential to drive growth and innovation.
Modernising Pharmacy Supply Chains
The alliance focuses on enhancing pharmacy supply chain efficiency through advanced digital services. Pharmx and Sigma will collaborate on expanding global EDI capabilities and other technology solutions designed to streamline operations, improve data analytics, and support industry-wide growth. Pharmx’s CEO, Tom Culver, highlighted the milestone nature of this partnership, citing it as a catalyst for broadening Pharmx’s revenue streams and accelerating its expansion across Australia, New Zealand, and beyond.
Meanwhile, Sigma’s CEO, Vikesh Ramsunder, emphasised the strategic fit and shared growth objectives, noting the alliance’s potential to reduce complexity and unlock new value for both organisations.
Looking Ahead
While the incremental financial impact of the alliance remains unquantified pending further statements of work, the partnership is expected to enhance Pharmx’s Gateway, Marketplace, and Analytics platforms. The initial phase of the expanded partnership commenced on 23 February 2026, with deliverables to follow shortly.
Pharmx will host an investor briefing to discuss the alliance in detail, signalling transparency and engagement with shareholders as this strategic relationship unfolds.
Bottom Line?
This alliance marks a pivotal step for Pharmx, setting the stage for deeper integration and growth in the evolving pharmacy technology landscape.
Questions in the middle?
- How will the alliance impact Pharmx’s revenue and profitability in the near term?
- What specific new digital services and markets will be targeted under Part B of the agreement?
- How might Sigma’s board representation influence Pharmx’s strategic direction?
